GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GeneDx (WGS), a genomic insights company, has announced the granting of 46,340 restricted stock units (RSUs) to ten newly-hired employees as employment inducement awards. The grants, effective March 15, 2025, were approved by the compensation committee under GeneDx's 2023 Equity Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest equally over a four-year period, contingent on continued employment. Each RSU represents the right to receive one share of GeneDx's Class A Common Stock upon settlement. The company specializes in rare disease diagnostics, offering exome and genome tests to enable personalized healthcare solutions.
GeneDx (WGS), un'azienda specializzata in genomica, ha annunciato l'assegnazione di 46.340 unità di azioni vincolate (RSU) a dieci nuovi dipendenti come premi di assunzione. Le concessioni, efficaci dal 15 marzo 2025, sono state approvate dal comitato per la remunerazione nell'ambito del Piano di Incentivazione Azionaria 2023 di GeneDx e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4).
Le RSU matureranno in modo equo su un periodo di quattro anni, a condizione del mantenimento dell'impiego. Ogni RSU rappresenta il diritto di ricevere un'azione della Classe A delle Azioni Ordinarie di GeneDx al momento della liquidazione. L'azienda è specializzata nella diagnostica delle malattie rare, offrendo test dell'esoma e del genoma per consentire soluzioni sanitarie personalizzate.
GeneDx (WGS), una empresa de conocimientos genómicos, ha anunciado la concesión de 46,340 unidades de acciones restringidas (RSUs) a diez nuevos empleados como premios de inducción laboral. Las concesiones, efectivas a partir del 15 de marzo de 2025, fueron aprobadas por el comité de compensación bajo el Plan de Inducción de Capital 2023 de GeneDx y cumplen con la Regla de Cotización de Nasdaq 5635(c)(4).
Las RSUs se consolidarán de manera equitativa durante un período de cuatro años, condicionado a la continuación del empleo. Cada RSU representa el derecho a recibir una acción de las Acciones Comunes Clase A de GeneDx al momento de la liquidación. La empresa se especializa en diagnósticos de enfermedades raras, ofreciendo pruebas de exoma y genoma para permitir soluciones de atención médica personalizadas.
GeneDx (WGS), 유전체 통찰력을 제공하는 회사가 46,340개의 제한 주식 단위 (RSU)를 새로 채용된 10명의 직원에게 고용 유인 보상으로 부여한다고 발표했습니다. 이 보상은 2025년 3월 15일부터 유효하며, GeneDx의 2023년 자본 유인 계획에 따라 보상 위원회에 의해 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
RSU는 계속 고용되는 조건 하에 4년 동안 균등하게 부여됩니다. 각 RSU는 정산 시 GeneDx의 A 클래스 보통주 1주를 받을 수 있는 권리를 나타냅니다. 이 회사는 희귀 질환 진단에 전문화되어 있으며, 개인 맞춤형 의료 솔루션을 제공하기 위해 엑솜 및 유전체 검사를 제공합니다.
GeneDx (WGS), une entreprise spécialisée dans les insights génomiques, a annoncé l'octroi de 46 340 unités d'actions restreintes (RSU) à dix nouveaux employés en tant que primes d'incitation à l'embauche. Les attributions, effectives à partir du 15 mars 2025, ont été approuvées par le comité de rémunération dans le cadre du Plan d'Incitation en Actions 2023 de GeneDx et sont conformes à la Règle de Cotation Nasdaq 5635(c)(4).
Les RSU seront acquises de manière égale sur une période de quatre ans, sous réserve de la continuité de l'emploi. Chaque RSU représente le droit de recevoir une action des Actions Ordinaires de Classe A de GeneDx lors du règlement. L'entreprise est spécialisée dans le diagnostic des maladies rares, offrant des tests d'exome et de génome pour permettre des solutions de santé personnalisées.
GeneDx (WGS), ein Unternehmen für genomische Erkenntnisse, hat die Gewährung von 46.340 eingeschränkten Aktieneinheiten (RSUs) an zehn neu eingestellte Mitarbeiter als Anreiz für die Beschäftigung angekündigt. Die Zuwendungen, die ab dem 15. März 2025 wirksam sind, wurden vom Vergütungsausschuss im Rahmen des GeneDx Equity Inducement Plans 2023 genehmigt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
Die RSUs werden über einen vierjährigen Zeitraum gleichmäßig fällig, abhängig von der Fortsetzung der Beschäftigung. Jede RSU stellt das Recht dar, bei der Abwicklung eine Aktie der GeneDx Klasse A Stammaktien zu erhalten. Das Unternehmen ist auf die Diagnostik seltener Krankheiten spezialisiert und bietet Exom- und Genomtests an, um personalisierte Gesundheitslösungen zu ermöglichen.
- None.
- None.
The RSUs will vest in equal annual installments over a four-year period, subject to the employee’s continued service with GeneDx on each applicable vesting date. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320830225/en/
Investor Relations:
Investors@GeneDx.com
Media:
Press@GeneDx.com
Source: GeneDx
FAQ
How many RSUs did GeneDx (WGS) grant to new employees in March 2025?
What is the vesting schedule for GeneDx's (WGS) March 2025 RSU grants?
Under which plan were the GeneDx (WGS) RSU inducement grants issued?
What do GeneDx (WGS) RSU holders receive upon settlement?
